TestingLandmark
2026 ACC/AHA multisociety guideline on the management of dyslipidemia (Blumenthal, Morris et al., Circulation 2026)
Original title: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
The guideline that retires the 2018 blood cholesterol guideline, published in Circulation and JACC in the spring of 2026: it widens the scope to dyslipidemias including hypertriglyceridemia and elevated lipoprotein(a), addresses evaluation, management and monitoring, and for Lp(a) moves the US toward universal once-in-a-lifetime measurement and risk-enhancer use in line with the NLA 2024 update. Leslie Cho's top-10 video in the Video section summarises it.
Original abstract
Aim: The "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia" retires and replaces the "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol."
Methods: A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline.
Structure: The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.